Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Sanofi Consumer Healthcare Indias shares finished Thursday 1.42% higher at Rs 4,815 a share, with a market capitalisation of ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850 million floating rate notes, due March 2027, bearing interest at ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNY – Research Report) yesterday and set a price target of $63.00. The ...

Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.